Teva Pharmaceutical Industries Ltd. (TEVA)

20.99
0.10 0.47
NYSE : Health Technology
Prev Close 21.09
Open 21.19
Day Low/High 20.94 / 21.22
52 Wk Low/High 10.85 / 33.82
Volume 6.06M
Avg Volume 11.17M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 21.41B
EPS -16.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dow Closes Higher as Wall Street Weighs Rising Rates

Dow Closes Higher as Wall Street Weighs Rising Rates

The Dow, S&P 500 and Nasdaq all rose on Wednesday.

Teva Shares Jump After Warren Buffett Doubles Stake in Drugmaker

Teva Shares Jump After Warren Buffett Doubles Stake in Drugmaker

Berkshire Hathaway hiked its stake in the drugmaker, which is undergoing a restructuring, to 40.5 million shares as of the end of March.

Teva Shows Progress on Restructuring But Investors Want More

Teva Shows Progress on Restructuring But Investors Want More

The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.

Dow Rises Slightly but S&P 500 and Nasdaq Finish Lower After Volatile Session

Dow Rises Slightly but S&P 500 and Nasdaq Finish Lower After Volatile Session

Shares of Tesla Inc., which reported earnings on Wednesday, fell by 5.5%

Teva Shares Spike After Q1 Earnings Beat, Full Year Forecast Boost

Teva Shares Spike After Q1 Earnings Beat, Full Year Forecast Boost

Teva shares edged into positive territory for the year Thursday after a stronger-than-expected start to the year allowed CEO Kåre Schultz to boost the generic drugmaker's 2018 earnings forecast.

McDonald's, Nucor, Ball Corp.: 'Mad Money' Lightning Round

McDonald's, Nucor, Ball Corp.: 'Mad Money' Lightning Round

Jim Cramer shines a spotlight on McDonald's, Nucor, Ball Corp. United States Steel, Teva Pharmaceuticals, Chicago Mercantile Exchange and more.

Fools Rush In: Cramer's 'Mad Money' Recap (Wednesday 4/25/18)

Fools Rush In: Cramer's 'Mad Money' Recap (Wednesday 4/25/18)

Jim Cramer says he's still optimistic, and he doesn't want investors to give up. But he has 12 reasons to also remain cautious -- especially about Fridays.

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.

P&G Buys Consumer Healthcare Unit From Germany's Merck in First Peltz-Era Deal

P&G Buys Consumer Healthcare Unit From Germany's Merck in First Peltz-Era Deal

Procter & Gamble will pay around $4.2 billion for the consumer healthcare unit of Merck KGaA in the first major deal for the group since activist investor Nelson Peltz joined the board last month.

Mylan's Stock Gets Bump After Investor Day

Mylan's Stock Gets Bump After Investor Day

Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

American Medical Association Rejects Idea of Time Limits on Opioid Scripts

While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

Trump's China Tariffs Could Hurt Generic Drug Companies and Increase Prices

As President Trump tees up a set of 25% tariffs on a wide range of products against China trade, generic drug makers as well as their patients likely will be affected.

Teva Analyst: Wall Street's Forecasts Look 'Overly Ambitious'

Teva Analyst: Wall Street's Forecasts Look 'Overly Ambitious'

RBC's Randall Stanicky says concerns have moved from being about global generic growth to Teva's branded drug business.

Teva Announces The Launch Of A Generic Version Of Lialda® In The United States

Teva Announces The Launch Of A Generic Version Of Lialda® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Lialda ®1 (mesalamine) delayed-release tablets, 1.

Teva Announces The Launch Of A Generic Version Of ALOXI® In The United States

Teva Announces The Launch Of A Generic Version Of ALOXI® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the launch of a generic version of ALOXI ®1 (palonosetron HCI) injection, 0.

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med Pot

Novartis subsidiary Sandoz Canada will work with cannabis producer Tilray to produce non-smokable medical cannabis products in Canada, becoming the first Big Pharma company to get into medical pot.

Trump Opioid Policy Rollout Includes Call for Death Penalty for Dealers

Trump Opioid Policy Rollout Includes Call for Death Penalty for Dealers

President Trump made a long-awaited announcement of his administration's opioid plan in a New Hampshire speech that was part policy roll out and part political rally.

Teva To Present At The Cowen & Company 38th Annual Healthcare Conference

Teva To Present At The Cowen & Company 38th Annual Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Cowen & Company 38 th Annual Healthcare Conference in Boston, MA.

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

Generic Drug Sector Shifting With Legal Pressure, Changes at FDA

A massive price-fixing lawsuit brought by 45 states against a group of generic drug producers as well as a changing of the guard at the Food and Drug Administration may lead to changes in the generic drug sector.

Teva Announces Upsizing And Successful Pricing Of $4.5 Billion Of Senior Notes

Teva Announces Upsizing And Successful Pricing Of $4.5 Billion Of Senior Notes

Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) ("Teva") announced today that it successfully priced the offering of $4.

Study: Over-the-Counter Meds More Effective For Chronic Back Pain Than Opioids

Study: Over-the-Counter Meds More Effective For Chronic Back Pain Than Opioids

A study published by the Journal of the American Medical Association shows OTC drugs were more effective in cutting pain for chronic back pain and osteoarthritis hip and knee patients than opioids.

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Mylan Breaks Out Amid Generic Malaise; Target Shorts Rejoice -- ICYMI

Here's what you need to know now for Tuesday, March 6.

TheStreet Quant Rating: D+ (Sell)